Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
Purpose To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. Methods Matching-adjusted i...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-10-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1707754 |
| _version_ | 1797683643239366656 |
|---|---|
| author | Deepak M. W. Balak Jose-Manuel Carrascosa Stamatis Gregoriou Piergiacomo Calzavara-Pinton Anthony Bewley Joana Antunes Martin E. Nyeland Marta G. Viola Laura M. Sawyer Lidia Becla |
| author_facet | Deepak M. W. Balak Jose-Manuel Carrascosa Stamatis Gregoriou Piergiacomo Calzavara-Pinton Anthony Bewley Joana Antunes Martin E. Nyeland Marta G. Viola Laura M. Sawyer Lidia Becla |
| author_sort | Deepak M. W. Balak |
| collection | DOAJ |
| description | Purpose To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. Methods Matching-adjusted indirect comparisons of four-week PASI-75 responses of Cal/BD foam were performed versus 12-week responses of methotrexate, acitretin, fumaric acid esters (FAE) and 16-week responses of apremilast. Analyses took a payer perspective and included drug, physician visit and monitoring costs. Results In all countries, Cal/BD foam generated the lowest cost per responder (CPR). Against methotrexate, apremilast and acitretin, Cal/BD foam generated response for less than €190 in Italy, €195 in Portugal, €216 in Greece, £218 in the United Kingdom, €250 in Belgium, €319 in Spain, and €359 in the Netherlands. Relative to treatment with FAE, Cal/BD foam resulted in response for less than €298, €430, €382 and £262 in Belgium, the Netherlands, Spain and the United Kingdom, respectively. For Cal/BD foam, apremilast and FAE, total costs were driven by drug costs; for methotrexate and acitretin, by monitoring. Conclusions Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population. |
| first_indexed | 2024-03-12T00:17:31Z |
| format | Article |
| id | doaj.art-e7f575431899423e9eb44d7c0f95e126 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:31Z |
| publishDate | 2021-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-e7f575431899423e9eb44d7c0f95e1262023-09-15T14:23:04ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-10-0132770170810.1080/09546634.2019.17077541707754Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countriesDeepak M. W. Balak0Jose-Manuel Carrascosa1Stamatis Gregoriou2Piergiacomo Calzavara-Pinton3Anthony Bewley4Joana Antunes5Martin E. Nyeland6Marta G. Viola7Laura M. Sawyer8Lidia Becla9Department of Dermatology and Allergology, University Medical Centre UtrechtDermatology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de BarcelonaDepartment of Dermatology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros HospitalDermatology Department, University of BresciaBarts Health NHS Trust and Queen Mary University of LondonServiço de Dermatologia, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPELEO Pharma A/SSymmetron LimitedSymmetron LimitedLEO Pharma A/SPurpose To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. Methods Matching-adjusted indirect comparisons of four-week PASI-75 responses of Cal/BD foam were performed versus 12-week responses of methotrexate, acitretin, fumaric acid esters (FAE) and 16-week responses of apremilast. Analyses took a payer perspective and included drug, physician visit and monitoring costs. Results In all countries, Cal/BD foam generated the lowest cost per responder (CPR). Against methotrexate, apremilast and acitretin, Cal/BD foam generated response for less than €190 in Italy, €195 in Portugal, €216 in Greece, £218 in the United Kingdom, €250 in Belgium, €319 in Spain, and €359 in the Netherlands. Relative to treatment with FAE, Cal/BD foam resulted in response for less than €298, €430, €382 and £262 in Belgium, the Netherlands, Spain and the United Kingdom, respectively. For Cal/BD foam, apremilast and FAE, total costs were driven by drug costs; for methotrexate and acitretin, by monitoring. Conclusions Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population.http://dx.doi.org/10.1080/09546634.2019.1707754psoriasiscalcipotriol/betamethasone dipropionate cutaneous foamtopical therapysystemic therapycost per response |
| spellingShingle | Deepak M. W. Balak Jose-Manuel Carrascosa Stamatis Gregoriou Piergiacomo Calzavara-Pinton Anthony Bewley Joana Antunes Martin E. Nyeland Marta G. Viola Laura M. Sawyer Lidia Becla Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries Journal of Dermatological Treatment psoriasis calcipotriol/betamethasone dipropionate cutaneous foam topical therapy systemic therapy cost per response |
| title | Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries |
| title_full | Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries |
| title_fullStr | Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries |
| title_full_unstemmed | Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries |
| title_short | Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries |
| title_sort | cost per pasi 75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven european countries |
| topic | psoriasis calcipotriol/betamethasone dipropionate cutaneous foam topical therapy systemic therapy cost per response |
| url | http://dx.doi.org/10.1080/09546634.2019.1707754 |
| work_keys_str_mv | AT deepakmwbalak costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT josemanuelcarrascosa costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT stamatisgregoriou costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT piergiacomocalzavarapinton costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT anthonybewley costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT joanaantunes costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT martinenyeland costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT martagviola costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT lauramsawyer costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries AT lidiabecla costperpasi75responderofcalcipotriolplusbetamethasonedipropionatecutaneousfoamversusnonbiologicsystemictherapiesforthetreatmentofplaquepsoriasisinseveneuropeancountries |